Parbendazole free base | CAS#14255-87-9

MedKoo Cat#: 330168 | Name: Parbendazole free base

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Parbendazole is an anthelmintic drug. Parbendazole is a potent inhibitor of microtubule assembly, destabilizes tubulin and exhibits a broad-spectrum anthelmintic activity.

Chemical Structure

Parbendazole free base

CAS#14255-87-9 (free base)

Theoretical Analysis

MedKoo Cat#: 330168

Name: Parbendazole free base

CAS#: 14255-87-9 (free base)

Chemical Formula: C13H17N3O2

Exact Mass: 247.1321

Molecular Weight: 247.30

Elemental Analysis: C, 63.14; H, 6.93; N, 16.99; O, 12.94

Price and Availability

Size	Price	Availability
100mg	USD 450.00	2 Weeks
200mg	USD 750.00	2 Weeks
500mg	USD 1,650.00	2 Weeks
1g	USD 2,950.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

14255-87-9 (free base) 83601-81-4 (HCl)

Synonym

Parbendazole; PBZ; PBZ (fungicide); Helatac; Helmatac; SKF 29044; SKF-29044; SKF29044;

IUPAC/Chemical Name

N-(6-Butyl-1H-benzimidazol-2-yl)carbamic Acid Methyl Ester

InChi Key

YRWLZFXJFBZBEY-UHFFFAOYSA-N

InChi Code

InChI=1S/C13H17N3O2/c1-3-4-5-9-6-7-10-11(8-9)15-12(14-10)16-13(17)18-2/h6-8H,3-5H2,1-2H3,(H2,14,15,16,17)

SMILES Code

O=C(OC)NC1=NC2=CC=C(CCCC)C=C2N1

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Parbendazole is a potent inhibitor of microtubule assembly, destabilizes tubulin, with an EC50 of 530 nM, and exhibits a broad-spectrum anthelmintic activity.

In vitro activity:

Notably, parbendazole was the most potent benzimidazole affecting PC cell viability, with half maximal inhibitory concentration (IC50) values in the nanomolar range. The drug markedly inhibited proliferation, clonogenicity and migration of PC cell lines through mechanisms involving alteration of microtubule organization and formation of irregular mitotic spindles. Moreover, parbendazole interfered with cell cycle progression promoting G2/M arrest, followed by the emergence of enlarged, polyploid cells. Reference: Cancers (Basel). 2019 Dec 17;11(12):2042. https://pubmed.ncbi.nlm.nih.gov/31861153/

In vivo activity:

HN6 xenograft model was used to evaluate parbendazole anti-tumor efficacy. In this study, parbendazole showed dose-dependent tumor growth inhibition without altering the bodyweight of mice (Fig. 7A and B), indicating its excellent in vivo anti-tumor efficacy and low toxicity. Furthermore, this study further conducted another evaluation of in vivo anticancer activity by using a zebrafish bearing HN6 xenograft and observed a good therapeutic effect of parbendazole as well (Fig. 7C and D). Reference: Acta Pharm Sin B. 2022 May;12(5):2429-2442. https://pubmed.ncbi.nlm.nih.gov/35646536/

	Solvent	mg/mL	mM
Solubility
	DMSO	3.5	14.15

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 247.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Florio R, Veschi S, di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, Cataldi A, Amoroso R, Cama A, De Lellis L. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. Cancers (Basel). 2019 Dec 17;11(12):2042. doi: 10.3390/cancers11122042. PMID: 31861153; PMCID: PMC6966614. 2. Foster KE, Burland TG, Gull K. A mutant beta-tubulin confers resistance to the action of benzimidazole-carbamate microtubule inhibitors both in vivo and in vitro. Eur J Biochem. 1987 Mar 16;163(3):449-55. doi: 10.1111/j.1432-1033.1987.tb10890.x. PMID: 3830165. 3. Liang D, Yu C, Ma Z, Yang X, Li Z, Dong X, Qin X, Du L, Li M. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning. Acta Pharm Sin B. 2022 May;12(5):2429-2442. doi: 10.1016/j.apsb.2021.12.005. Epub 2021 Dec 20. PMID: 35646536; PMCID: PMC9136614.

In vitro protocol:

In vivo protocol:

1. Liang D, Yu C, Ma Z, Yang X, Li Z, Dong X, Qin X, Du L, Li M. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning. Acta Pharm Sin B. 2022 May;12(5):2429-2442. doi: 10.1016/j.apsb.2021.12.005. Epub 2021 Dec 20. PMID: 35646536; PMCID: PMC9136614.

1: Matsuo H, Inagami A, Ito Y, Ito N, Iyoda S, Harata Y, Higashitani M, Shoji K, Tanaka M, Noura M, Mikami T, Kato I, Takita J, Nakahata T, Adachi S. Parbendazole as a promising drug for inducing differentiation of acute myeloid leukemia cells with various subtypes. Commun Biol. 2024 Jan 24;7(1):123. doi: 10.1038/s42003-024-05811-8. PMID: 38267545; PMCID: PMC10808455. 2: Iragavarapu-Charyulu V, Shakya R, Robinson P, Guzmán E, Tyulmenkova A, Pino JL, Isgor C. A novel treatment to enhance survival for end stage triple negative breast cancer using repurposed veterinary anthelmintics combined with gut‑supporting/immune enhancing molecules. Oncol Rep. 2024 Feb;51(2):31. doi: 10.3892/or.2023.8690. Epub 2023 Dec 22. PMID: 38131223. 3: Garg A, Karhana S, Bano A, Khan IA, Reeta, Nidhi, Khan MA. Network pharmacology and molecular docking study-based approach to explore mechanism of benzimidazole-based anthelmintics for the treatment of lung cancer. J Biomol Struct Dyn. 2023 Sep 23:1-22. doi: 10.1080/07391102.2023.2258419. Epub ahead of print. PMID: 37740654. 4: Sada Del Real K, Rubio A. Discovering the mechanism of action of drugs with a sparse explainable network. EBioMedicine. 2023 Sep;95:104767. doi: 10.1016/j.ebiom.2023.104767. Epub 2023 Aug 24. PMID: 37633093; PMCID: PMC10474372. 5: Werner L, Gliem M, Rychlik N, Pavic G, Reiche L, Kirchhoff F, Silva Oliveira Junior M, Gruchot J, Meuth SG, Küry P, Göttle P. A Novel Ex Vivo Model to Study Therapeutic Treatments for Myelin Repair following Ischemic Damage. Int J Mol Sci. 2023 Jun 30;24(13):10972. doi: 10.3390/ijms241310972. PMID: 37446147; PMCID: PMC10341986. 6: Bayraktar A, Li X, Kim W, Zhang C, Turkez H, Shoaie S, Mardinoglu A. Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer's disease patients. J Transl Med. 2023 May 20;21(1):332. doi: 10.1186/s12967-023-04192-6. PMID: 37210557; PMCID: PMC10199278. 7: Alipour A, Hatam G, Seradj H. Microtubule Disruption Without Learning Impairment in the Unicellular Organism, Paramecium: Implications for Information Processing in Microtubules. Basic Clin Neurosci. 2022 Jan-Feb;13(1):139-152. doi: 10.32598/bcn.2021.2462.1. Epub 2022 Jan 1. PMID: 36589025; PMCID: PMC9790103. 8: Oliveira CC, Costa DFL, Limeira CH, Nogueira DB, Nascimento BHR, Vaz AFM. Anthelmintic intoxication in goats and sheep: A systematic review. Res Vet Sci. 2022 Dec 20;152:657-662. doi: 10.1016/j.rvsc.2022.09.038. Epub 2022 Oct 5. PMID: 36219891. 9: Liang D, Yu C, Ma Z, Yang X, Li Z, Dong X, Qin X, Du L, Li M. Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning. Acta Pharm Sin B. 2022 May;12(5):2429-2442. doi: 10.1016/j.apsb.2021.12.005. Epub 2021 Dec 20. PMID: 35646536; PMCID: PMC9136614. 10: Liang D, Yu C, Ma Z, Hu M, Wang J, Dong X, Du L, Li M. Design, synthesis and biological evaluation of new parbendazole derivatives for the treatment of HNSCC. Eur J Med Chem. 2022 Aug 5;238:114450. doi: 10.1016/j.ejmech.2022.114450. Epub 2022 May 11. PMID: 35576703. 11: Lei JH, Ma LL, Xian JH, Chen H, Zhou JJ, Chen H, Lei Q, Li YY, Wang YY, Wang YX. Structural insights into targeting of the colchicine binding site by ELR510444 and parbendazole to achieve rational drug design. RSC Adv. 2021 May 25;11(31):18938-18944. doi: 10.1039/d1ra01173a. PMID: 35478655; PMCID: PMC9033620. 12: Florio R, Carradori S, Veschi S, Brocco D, Di Genni T, Cirilli R, Casulli A, Cama A, De Lellis L. Screening of Benzimidazole-Based Anthelmintics and Their Enantiomers as Repurposed Drug Candidates in Cancer Therapy. Pharmaceuticals (Basel). 2021 Apr 17;14(4):372. doi: 10.3390/ph14040372. PMID: 33920661; PMCID: PMC8072969. 13: Manousi A, Göttle P, Reiche L, Cui QL, Healy LM, Akkermann R, Gruchot J, Schira-Heinen J, Antel JP, Hartung HP, Küry P. Identification of novel myelin repair drugs by modulation of oligodendroglial differentiation competence. EBioMedicine. 2021 Mar;65:103276. doi: 10.1016/j.ebiom.2021.103276. Epub 2021 Mar 10. PMID: 33714029; PMCID: PMC7970057. 14: Son DS, Lee ES, Adunyah SE. The Antitumor Potentials of Benzimidazole Anthelmintics as Repurposing Drugs. Immune Netw. 2020 Aug 4;20(4):e29. doi: 10.4110/in.2020.20.e29. PMID: 32895616; PMCID: PMC7458798. 15: Florio R, Veschi S, di Giacomo V, Pagotto S, Carradori S, Verginelli F, Cirilli R, Casulli A, Grassadonia A, Tinari N, Cataldi A, Amoroso R, Cama A, De Lellis L. The Benzimidazole-Based Anthelmintic Parbendazole: A Repurposed Drug Candidate That Synergizes with Gemcitabine in Pancreatic Cancer. Cancers (Basel). 2019 Dec 17;11(12):2042. doi: 10.3390/cancers11122042. PMID: 31861153; PMCID: PMC6966614. 16: Guo L, Wu X, Liu L, Kuang H, Xu C. Gold Nanoparticle-Based Paper Sensor for Simultaneous Detection of 11 Benzimidazoles by One Monoclonal Antibody. Small. 2018 Feb;14(6). doi: 10.1002/smll.201701782. Epub 2017 Dec 20. PMID: 29266723. 17: Brum AM, van de Peppel J, Nguyen L, Aliev A, Schreuders-Koedam M, Gajadien T, van der Leije CS, van Kerkwijk A, Eijken M, van Leeuwen JPTM, van der Eerden BCJ. Using the Connectivity Map to discover compounds influencing human osteoblast differentiation. J Cell Physiol. 2018 Jun;233(6):4895-4906. doi: 10.1002/jcp.26298. Epub 2018 Jan 15. PMID: 29194609. 18: Brum AM, van de Peppel J, van der Leije CS, Schreuders-Koedam M, Eijken M, van der Eerden BC, van Leeuwen JP. Connectivity Map-based discovery of parbendazole reveals targetable human osteogenic pathway. Proc Natl Acad Sci U S A. 2015 Oct 13;112(41):12711-6. doi: 10.1073/pnas.1501597112. Epub 2015 Sep 29. PMID: 26420877; PMCID: PMC4611615. 19: Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, Chen A, Hamill J, De Silva N, Conrad DP, Atkins H, Garson K, Ilkow C, Kærn M, Vanderhyden B, Sonenberg N, Alain T, Le Boeuf F, Bell JC, Diallo JS. Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing. Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410. PMID: 25817275. 20: Wales CT, Taylor FR, Higa AT, McAllister HA, Jacobs AT. ERK-dependent phosphorylation of HSF1 mediates chemotherapeutic resistance to benzimidazole carbamates in colorectal cancer cells. Anticancer Drugs. 2015 Jul;26(6):657-66. doi: 10.1097/CAD.0000000000000231. PMID: 25811962.